MyFinsight
Home
Blog
About
Proceeds from public
offering of common stock...
$300,000K
Maturities of investments
$18,000K
(-68.56%↓ Y/Y)
Proceeds from exercise of
stock options
$67K
(-51.45%↓ Y/Y)
Proceeds from purchase of
espp shares
-$7K
(94.78%↑ Y/Y)
Net cash provided by
financing activities
$283,269K
(169522.16%↑ Y/Y)
Net cash provided by
investing activities
$17,585K
(-43.44%↓ Y/Y)
Canceled cashflow
$16,805K
Canceled cashflow
$415K
Net increase
(decrease) in cash, cash...
$280,499K
(2525.62%↑ Y/Y)
Canceled cashflow
$20,355K
Issuance costs paid in
connection with public...
$16,793K
Payments on finance
leases
$12K
(-81.82%↓ Y/Y)
Accrued expenses
(including related party...
$4,020K
(371.44%↑ Y/Y)
Stock-based compensation
$1,865K
(-48.21%↓ Y/Y)
Depreciation and
amortization
$692K
(-45.47%↓ Y/Y)
Operating lease
right-of-use asset and lease...
$244K
(1061.90%↑ Y/Y)
Purchases of property and
equipment
$415K
(-73.50%↓ Y/Y)
Net cash used in
operating activities
-$20,355K
(52.47%↑ Y/Y)
Canceled cashflow
$6,821K
Net loss
-$25,005K
(39.84%↑ Y/Y)
Prepaid expenses and
other current assets
$783K
(-78.33%↓ Y/Y)
Accounts payable
(including related party...
-$780K
(-364.29%↓ Y/Y)
Other long-term
assets
$351K
(253.28%↑ Y/Y)
Other receivables
(including related party...
$141K
(221.55%↑ Y/Y)
Accretion of discounts and
amortization of premiums on...
$116K
(-90.58%↓ Y/Y)
Back
Back
Cash Flow
Artiva Biotherapeutics, Inc. (ARTV)
Artiva Biotherapeutics, Inc. (ARTV)
source: myfinsight.com